Intralymphatic eASC Administration in Healthy Volunteers

NCT01743222 · clinicaltrials.gov ↗

PHASE1

Phase

COMPLETED

Status

10

Enrollment

INDUSTRY

Sponsor class

Conditions

Localized Adverse Reaction to Administration of Drug

Interventions

GENETIC: eASC
DRUG: Placebo

Sponsor

Tigenix S.A.U.